Table 4.
Hazard ratio of cancer progression for ALDH2*2 carriers estimated from a 6-month observation
| Rs671 | HR | 95% CI | p | AIC | |
|---|---|---|---|---|---|
| Model 1 | (−) | 1.00 | (reference) | 464 | |
| (+) | 3.33 | (1.80–6.15) | 0.0001 | ||
| Model 2 | (−) | 1.00 | (reference) | 465 | |
| (+) | 4.89 | (2.37–10.1) | < 0.0001 | ||
| Model 3 | (−) | 1.00 | (reference) | 460 | |
| (+) | 5.04 | (2.48–10.2) | < 0.0001 | ||
| Model 4 | (−) | 1.00 | (reference) | 444 | |
| (+) | 5.42 | (2.65–11.1) | < 0.0001 |
N = 105. Rs671(−); ALDH2*1/*1, rs671(+); ALDH2*1/*2 or ALDH2*2/*2, HR Hazard ratio by Cox proportional hazard model, CI Confidence interval, AIC Akaike’s Information Criterion
Model 1: adjusted for sex, age (continuous), Brinkman Index (< 100, < 1000, ≥1000) (ordinal), type of first immune checkpoint inhibitor (ICI), tumor histotype, TNM classification (categorical), number of lines (first, second, third, and later) (categorical), and chemotherapy with ICI
Model 2: adjusted for the covariates in model 1 and the PD-L1 positivity ratio (< 1, < 50%, ≥50%, unassessed)
Model 3: adjusted for the covariates in model 2 and EGFR mutation ((+), (−), unassessed)
Model 4: adjusted for the covariates in model 3, log (neutrophil count in peripheral blood) and log (lymphocyte count in peripheral blood)